Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases

Bianchi, Luca; Orlandi, Augusto; Campione, Elena; Angeloni, Caterina; Costanzo, Antonio; Spagnoli, Luigi Giusto; Chimenti, Sergio

doi:10.1111/j.1365-2133.2004.06044.x

Cited by 62 publications

(47 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Oral retinoids are only moderately effective as a chemopreventive agent for BCC, and their multiple side effects limit their widespread use (Wright et al, 2006). Treatment of sporadic BCCs with topical retinoids such as tazarotene can be successful; however complete tumor regression occurs in less than 50% of BCCs so treated (Bianchi et al, 2004). A retinoid precursor, β-carotene, and other less toxic agents such as non-steroidal anti-inflammatory agents (NSAIDs), do not have a significant effect in lowering BCC risk (Frieling et al, 2000) (Grau et al, 2006).…”

mentioning

confidence: 99%

Novel Hedgehog pathway targets against basal cell carcinoma

Tang

Epstein

2007

Toxicology and Applied Pharmacology

View full text Add to dashboard Cite

The Hedgehog signaling pathway plays a key role in directing growth and patterning during embryonic development and is required in vertebrates for the normal development of many structures, including the neural tube, axial skeleton, skin, and hair. Aberrant activation of the Hedgehog (Hh) pathway in adult tissue is associated with the development of basal cell carcinoma (BCC), medulloblastoma, and a subset of pancreatic, gastro-intestinal, and other cancers. This review will provide an overview of what is known about the mechanisms by which activation of Hedgehog signaling leads to the development of BCCs and will review two recent papers suggesting that agents that modulate sterol levels might influence the Hh pathway. Thus, sterols may be a new therapeutic target for the treatment of BCCs, and readily available agents such as statins (HMG-CoA reductase inhibitors) or vitamin D might be helpful in reducing BCC incidence. Epidemiology of Basal cell carcinoma (BCC)Basal cell carcinoma (BCC), the most common of all human cancers, affects close to 1 million Americans a year. Over the past 40 years there has been a dramatic increase in the incidence of BCC, and it is estimated that nearly 30% of Caucasians living in areas of high ambient sun exposure will develop a BCC (Miller and Weinstock, 1994). Furthermore, the incidence of BCC is rising in younger populations, especially among women (Christenson et al., 2005). Although the case fatality rate of BCCs is low, the high incidence and frequent occurrence of multiple primary tumors in affected individuals leads to significant morbidity. BCCs characteristically arise in sun-exposed body areas, most commonly on the head and neck, but also occur on the trunk and extremities. There are three accepted environmental insults for BCC development: ultraviolet radiation (UV), ionizing radiation (IR), and arsenic. Interindividual differences in the susceptibility to BCC development have been recognized for many years. Epidemiologic studies have identified phenotypic features such as fair skin and freckling tendency that are associated with an increased susceptibility to BCCs (Rubin et al., 2005).It is generally accepted that BCC can be caused by UV exposure from the sun. While the risk of squamous cell carcinoma is strongly related to cumulative sun exposure, sunlight's exact role in BCC development remains less clear (Armstrong and Kricker, 2001). Thus, epidemiologic studies have shown that BCC risk correlates better with intermittent sun exposure (i.e. childhood sunburns, weekend sun exposure) than with cumulative lifetime sun exposure (Corona et al., 2001). Hence, the timing, dose, and duration of UV exposure are critical to carcinogenesis, but UV seems to have a different role in SCC versus BCC carcinogenesis development. Consistent with this, a randomized clinical trial of daily sunscreen use showed that sunscreen reduced the incidence of SCC but not BCC. The daily application of an SPF 15 sunscreen to the head, neck, arms, and hands over a 4-5 year period had no e...

show abstract

mentioning

confidence: 99%

Novel Hedgehog pathway targets against basal cell carcinoma

Tang

Epstein

2007

Toxicology and Applied Pharmacology

View full text Add to dashboard Cite

show abstract

“…Tazarotene has been preliminarily shown to be efficacious in the regression of small superficial and nodular BCC when applied topically in 0.1% gel formulation over a range of 6 weeks to 8 months, with one study reporting complete regression without recurrence to be 30.5% at 3-year follow-up [19].…”

Section: Discussionmentioning

confidence: 99%

“…Moreover topical remedies such as Imiquimod [18], 5-flurouracil [18], tazarotene [19], also have been used. However many side effects were encountered with this medication [18] [19]. Topical Imiquimod is approved by food and drug administration (FDA) only for superficial BCCs as large as 2 cm in diameter located on the neck, trunk, or extremities.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Basal Cell Carcinoma by Topical 25% Podophyllin Solution

Sharquie¹,

Noaimi²,

Al-Zoubaidi³

2015

JCDSA

View full text Add to dashboard Cite

K. E. Sharquie et al. 190 dophyllin applications. After 3 -5 days, the reaction became more exaggerated and ulceration developed, ended with crust formation. No evidence of systemic side effects was seen and this had been confirmed clinically and by laboratory during the sessions and one month later. Minimal or no scarring was noticed. Conclusions: Topical 25% podophyllin solution is a new, effective therapeutic modality in treatment of basal cell carcinoma which gives 96% cure, and it is highly recommended as alternative therapy in all type of basal cell carcinoma, single and multiple and for all ages especially for elderly patients and those who have surgeries phobia.

show abstract

“…Cilt kanseri hücrelerinde apoptoz indüklenerek ve hücre çoğalması baskılanarak etkili olmaktadır. Cilt irritasyonu yaratması ve uzun kullanım süreleri gerektirmesi ilacın kullanımında en önemli dezavantajlardır 41 .…”

Section: Bhk Tedavi Seçenekleri Ve Güncel Yaklaşımlarunclassified

Current Advances in the Treatment of Basal Cell Carcinoma

Çalış¹,

Uzun²

2016

Acta Oncol Tur.

View full text Add to dashboard Cite

ÖZETBazal hücreli karsinom, derinin en sık görülen malign tümörü olup insidansı giderek artmaktadır. Predispozan faktörler arasında en önemlisi güneş ışınlarına maruz kalmaktır. Bununla birlikte genetik hastalıklar, organ nakilleri ve immünsupresyon da bazal hücreli karsinom gelişimini tetiklemektedir. Oldukça nadir metastaz yapmasına rağmen lokal agresif seyreder. Ana tedavi şekli cerrahi olup cerrahiye aday olmayan hastalarda radyoterapi, kriyoterapi, kemoterapi ve hedgehog yolak inhibitörleri kullanılabilir. Bu derlemede bazal hücreli karsinomun tedavisi konusunda güncel gelişmeler tartışılmıştır.Anahtar Kelimeler: bazal hücreli karsinom, cerrahi, vismodegib ABSTRACT Basal cell carcinoma is the most commonly seen malignant tumor of the skin and its incidence is gradually increasing. Sun exposure is the single most important predisposing factor. In addition, genetic disorders, organ transplantations and immunesupression may trigger the development of basal cell carcinoma. Although it metastasizes rarely, its clinical course is local aggressive. The main treatment modality is surgery. In patients who are not candidates for surgery; radiotherapy, cryotherapy, chemotherapy and hedgehog pathway modulators can be used. In this review, current advances in the treatment of basal cell carcinoma is discussed.

show abstract

Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases

Cited by 62 publications

References 37 publications

Novel Hedgehog pathway targets against basal cell carcinoma

Novel Hedgehog pathway targets against basal cell carcinoma

Treatment of Basal Cell Carcinoma by Topical 25% Podophyllin Solution

Current Advances in the Treatment of Basal Cell Carcinoma

Contact Info

Product

Resources

About